1048-P: Fasting C-Peptide as a Predictor for Hypoglycemia Risk and HbA1c Reduction in Chinese T2DM Patients Switching from Premixed to Basal Insulin: A Post Hoc Analysis from the Optimization Study

Objective: To explore the predictive effect of baseline fasting C-peptide (FCP) on hypoglycemia risk, HbA1c reduction, and treatment satisfaction in Chinese T2DM individuals switching from premixed to basal insulin. Methods: Post-hoc analysis of the single-arm, 16 weeks, phase IV OPTIMIZATION study. At 16 weeks, the study showed a mean reduction in HbA1c of 0.51% with basal insulin treatment after switching from premix. Study completers with baseline FCP testing (n=297) were stratified according to HbA1c 1.0 nmol/L could be used for predicting a higher probability to reach HbA1c 0.4% (OR=3.19, 95%CI 1.54, 6.59). By dividing participants using FCP dichotomy, similar results were obtained in people with FCP >0.59 nmol/L. When combined with overall hypoglycemia, both thresholds of FCP >1.0 nmol/L (OR=2.78, 95%CI 1.36, 5.68) and >0.59 nmol/L (OR=1.83, 95%CI 1.01, 3.30) predicted HbA1c